Hy 50856

The ESCC cell lines KYSE30, KYSE410, and KYSE140 were gifts from Yoshikazu Shimada of Kyoto University (Sakyo‐ku, Kyoto‐shi, Kyoto, JAPAN) and cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher, Waltham, MA, USA). The Jurkat cell line was bought from national infrastructure of cell line resource and cultured in RPMI 1640 medium with 10% FBS. The B16f10 cell line was bought from national infrastructure of cell line resource and cultured in Dulbecco's modified eagle medium (DMEM) with 10% FBS. These were authenticated using short tandem repeat profiling. The stable overexpression cell lines KYSE30, KYSE140, and KYSE410 were cultured in RPMI 1640 with 10% FBS and 0.5μg/mL puromycin (Sigma, St Louis, MO, USA). The cells were culture condition was maintained at 37°C with 5% CO₂. For IFN‐γ treatment, cells were incubated with 50ng/mL IFN‐γ (Sigma,) for 24 h. For WP1066 treatment (S2796, Selleck Chemicals, Houston, Texas, USA), cells were incubated with 5μM WP1066 for 20 h. For Ruxolitinib treatment (HY‐50856, MedChemExpress, NJ, Princeton, USA) cells were incubated with 2μM ruxolitinib for 20 h.